Aliases & Classifications for Drug Dependence

MalaCards integrated aliases for Drug Dependence:

Name: Drug Dependence 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9974
ICD9CM 35 304.6 304.60
UMLS 69 C0029792

Summaries for Drug Dependence

Disease Ontology : 12 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary : Drug Dependence is related to antisocial personality disorder and hepatitis d. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Acamprosate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 29.7 ANKK1 DRD2 DRD3
2 hepatitis d 29.1 BDNF CRH DRD2 SLC6A4
3 personality disorder 27.4 BDNF CNR1 CRH DRD2 DRD3 OPRM1
4 hallucinogen dependence 22.9 ACKR1 ANKK1 BDNF CHRM2 CHRNA6 CHRNB3
5 substance dependence 11.0
6 cocaine dependence 10.9
7 intracranial cavernous angioma 10.7 DRD2 SLC6A4
8 conjunctival pigmentation 10.7 CRH SLC6A4
9 chronic tympanitis 10.6 DRD2 OPRM1 PDYN
10 cyclotropia 10.6 OPRD1 OPRK1 OPRM1
11 malaria 10.6
12 cannabis dependence 10.6
13 opiate dependence 10.6
14 barbiturate dependence 10.6
15 cystic hygroma lethal cleft palate 10.6 CNR1 OPRM1
16 cervicitis 10.6 OPRD1 OPRK1 OPRM1
17 dissociative disorder 10.6 DRD3 SLC6A4
18 placenta disease 10.6 DRD2 DRD3
19 anosognosia 10.6 ANKK1 DRD2 SLC6A4
20 intermittent squint 10.6 CRH POMC
21 tongue disease 10.5 ANKK1 DRD2 SLC6A4
22 dementia - subcortical 10.5 CNR1 OPRM1
23 splenic abscess 10.5 DRD2 SLC6A4
24 renal pelvis carcinoma 10.5 CRH POMC
25 adult mesenchymal chondrosarcoma 10.5 PDYN POMC SLC6A4
26 x-linked dominant intellectual disability-epilepsy syndrome 10.5 CNR1 OPRK1
27 hyperthyroxinemia 10.5 DRD2 SLC6A4
28 actinobacillosis 10.5 CRH POMC
29 pyromania 10.4 DRD2 DRD3 SLC6A4
30 ulcerative blepharitis 10.4 CRH POMC
31 teebi kaurah syndrome 10.4 DRD2 DRD3
32 hypodermyasis 10.4 CRH POMC
33 cold-induced sweating syndrome 2 10.4 CRH DRD2 POMC
34 peroxisomal biogenesis disorders 10.4 CHRM2 DRD2
35 vallecula cancer 10.4 CRH POMC SLC6A4
36 may-hegglin anomaly 10.3 CRH POMC SLC6A4
37 ornithosis 10.3 DRD2 SLC6A4
38 postencephalitic parkinson disease 10.3 BDNF DRD2 SLC6A4
39 active cochlear meniere's disease 10.3 BDNF POMC
40 cecal benign neoplasm 10.2 ANKK1 DRD2 DRD3 SLC6A4
41 chronic dacryoadenitis 10.2 BDNF CRH SLC6A4
42 orbit lymphoma 10.1 CNR1 PENK
43 uterus intravascular leiomyomatosis 10.1 OPRK1 SLC6A4
44 transsexualism 10.1 BDNF CNR1 PDYN
45 west syndrome 10.0 BDNF CHRM2 CNR1
46 pauci-immune glomerulonephritis with anca 10.0 BDNF DRD2 DRD3 SLC6A4
47 hypoglycemic coma 10.0 BDNF CHRM2 CRH SLC6A4
48 colon mucinous adenocarcinoma 10.0 BDNF DRD2 DRD3 SLC6A4
49 bladder flat intraepithelial lesion 9.9 BDNF DRD2 DRD3 SLC6A4
50 aicardi-goutieres syndrome 2 9.9 BDNF DRD2 DRD3 SLC6A4

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

MGI Mouse Phenotypes related to Drug Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CHRNB3 CNR1 CRH DRD2 DRD3 OPRD1
2 homeostasis/metabolism MP:0005376 10.2 SLC6A4 CHRM2 CNR1 CRH DRD2 DRD3
3 growth/size/body region MP:0005378 10.11 CNR1 CRH DRD2 DRD3 OPRM1 PDYN
4 integument MP:0010771 10.07 BDNF CHRM2 CNR1 CRH DRD2 OPRD1
5 adipose tissue MP:0005375 10.02 CNR1 CRH DRD2 DRD3 OPRM1 PDYN
6 nervous system MP:0003631 10 BDNF CHRM2 CHRNA6 CNR1 CRH DRD2
7 digestive/alimentary MP:0005381 9.98 BDNF CNR1 DRD2 DRD3 OPRK1 OPRM1
8 endocrine/exocrine gland MP:0005379 9.95 OPRM1 POMC SLC6A4 BDNF CRH DRD2
9 no phenotypic analysis MP:0003012 9.61 BDNF CNR1 CRH DRD2 OPRD1 OPRM1
10 normal MP:0002873 9.23 BDNF CNR1 CRH DRD2 OPRL1 OPRM1

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 634)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
2
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 77337-76-9 71158
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
4
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
5
Lamotrigine Approved, Investigational Phase 4,Phase 2,Phase 3 84057-84-1 3878
6
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
9
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
11
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
12
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
13
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
14
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
15
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
16
Biperiden Approved Phase 4,Phase 3 514-65-8 2381
17
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 300-62-9 5826 3007
18
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
19
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
20
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 93-14-1 3516
21
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
22
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
23
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
24
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
25
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 537-46-2 10836
26
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
27
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
28
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
29
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
30
Prazosin Approved Phase 4,Phase 3,Phase 2,Phase 1 19216-56-9 4893
31
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
32
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
33
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
34
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
35
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
36
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
37
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
38
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
39
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 1 36505-84-7 2477
40
Sodium oxybate Approved Phase 4 502-85-2 5360545
41
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
42
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
43
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
44
Oxazepam Approved Phase 4,Early Phase 1 604-75-1 4616
45
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
46
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
47
Sorbitol Approved Phase 4 50-70-4 5780
48
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
49
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-41-2 439260
50
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296

Interventional clinical trials:

(show top 50) (show all 1652)

id Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
3 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
4 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
8 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4 Topiramate
9 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4 ondansetron, lidocaine
10 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4 Acamprosate;Placebo
11 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
12 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
13 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4 varenicline
14 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
15 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
16 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
17 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
18 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
19 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
20 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
21 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
22 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
23 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
24 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
25 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
26 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
27 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
28 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
29 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4 Dexmedetomidine
30 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
31 The Whole Day First Grade Program Completed NCT00257088 Phase 4
32 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic Completed NCT00381043 Phase 4 Acamprosate (Campral)
33 Extended-release Naltrexone for Alcohol Dependence in Primary Care Completed NCT00620750 Phase 4 Extended release injectable naltrexone (Vivitrol)
34 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
35 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
36 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
37 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
38 Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch) Completed NCT00000447 Phase 4 naltrexone (Revia);nicotine replacement patch
39 Effects of Chantix on Relapse Prevention for Smoking Cessation Completed NCT00948649 Phase 4 Placebo;Varenicline
40 Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription Completed NCT00244465 Phase 4
41 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
42 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Drug;Placebo
43 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
44 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
45 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
46 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms Completed NCT00332644 Phase 4 nicotine patch;nicotine lozenge;nicotine patch + nicotine lozenge;bupropion;bupropion + lozenge;placebo
47 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
48 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
49 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
50 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

MalaCards organs/tissues related to Drug Dependence:

39
Brain, Testes, Bone, Liver, Breast, Kidney, Lung

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 583)
id Title Authors Year
1
Comparisons of Alcohol and Drug Dependence in Terms of Attachments and Clinical Issues. ( 28742416 )
2017
2
Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model. ( 28290530 )
2017
3
The relationship between fear extinction and resilience to drug-dependence in rats. ( 28322983 )
2017
4
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. ( 28038466 )
2017
5
Patients with Infectious Endocarditis and Drug Dependence Have Worse Clinical Outcomes after Valvular Surgery. ( 28099093 )
2017
6
Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015. ( 28594786 )
2017
7
Predictors of Inpatient Treatment Completion among Females with Opioid Use Disorder: Findings from a Tertiary Care Drug Dependence Treatment Centre of India. ( 28852241 )
2017
8
Association of the PLCB1 gene with drug dependence. ( 28860459 )
2017
9
Abstinence From Drug Dependence After Bilateral Globus Pallidus Hypoxic-Ischemic Injury. ( 27311800 )
2016
10
Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. ( 27247820 )
2016
11
Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis. ( 27278934 )
2016
12
Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. ( 27046394 )
2016
13
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? ( 27208979 )
2016
14
Drug Dependence Treatment Awareness among Japanese Female Stimulant Drug Offenders. ( 27845738 )
2016
15
A Retrospective Chart Review of Treatment Completers Versus Noncompleters Among In-patients at a Tertiary Care Drug Dependence Treatment Centre in India. ( 27570339 )
2016
16
Profile of female patients seeking in-patient treatment for prescription opioid abuse from a tertiary care drug dependence treatment centre from India. ( 26997020 )
2016
17
Barriers in Access to the Treatment for People with Gambling Disorders. Are They Different from Those Experienced by People with Alcohol and/or Drug Dependence? ( 27832520 )
2016
18
Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. ( 26194548 )
2016
19
Ibogaine for treating drug dependence. What is a safe dose? ( 27426011 )
2016
20
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. ( 27230395 )
2016
21
Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial. ( 27428201 )
2016
22
Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs. ( 27241554 )
2016
23
Evidence for Association Between Low Frequency Variants in CHRNA6/CHRNB3 and Antisocial Drug Dependence. ( 27085880 )
2016
24
Three Types of Adverse Childhood Experiences, and Alcohol and Drug Dependence Among Adults: An Investigation Using Population-Based Data. ( 27326749 )
2016
25
Barriers to community-based drug dependence treatment: implications for police roles, collaborations and performance indicators. ( 27435714 )
2016
26
Evidence of Shared Genome-Wide Additive Genetic Effects on Interpersonal Trauma Exposure and Generalized Vulnerability to Drug Dependence in a Population of Substance Users. ( 27214850 )
2016
27
Stressful Events and Other Predictors of Remission from Drug Dependence in the United States: Longitudinal Results from a National Survey. ( 27776676 )
2016
28
Illicit Drug Dependence ( 27227249 )
2016
29
Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: a functional analysis approach. ( 27356948 )
2016
30
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence. ( 27424166 )
2016
31
[Role of intracellular Ca2+ dynamics in the development of drug dependence--Participation of Inositol 1,4,5-trisphosphate receptors]. ( 26255430 )
2015
32
Salutogenesis: Contextualising place and space in the policies and politics of recovery from drug dependence (UK). ( 26616849 )
2015
33
Association between experience of child abuse and severity of drug addiction measured by the Addiction Severity Index among Japanese drug-dependent patients. ( 25741639 )
2015
34
Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. ( 25424661 )
2015
35
Negative mood reverses devaluation of goal-directed drug-seeking favouring an incentive learning account of drug dependence. ( 26041336 )
2015
36
Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. ( 26470779 )
2015
37
The Two Faces of Social Interaction Reward in Animal Models of Drug Dependence. ( 26088685 )
2015
38
WHO Expert Committee on Drug Dependence. Thirty-sixth report. ( 26062388 )
2015
39
Stress and Drug Dependence Differentially Modulate Norepinephrine Signaling in Animals with Varied HPA Axis Function. ( 25601230 )
2015
40
Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis. ( 25500252 )
2015
41
Testing for drugs in exhaled breath collected with ExaBreathAr in a drug dependence population: comparison with data obtained in urine after LC-MS/MS analyses. ( 26222873 )
2015
42
Can psychedelic compounds play a part in drug dependence therapy? ( 25561484 )
2015
43
Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence. ( 26491869 )
2015
44
Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. ( 24685458 )
2014
45
Research gaps on methadone harms and comparative harms: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( 24685460 )
2014
46
Modifying the risk associated with an impulsive temperament: a prospective study of drug dependence treatment. ( 24924874 )
2014
47
Treating drug dependence with the aid of ibogaine: A retrospective study. ( 25271214 )
2014
48
Self-Efficacy and Social Networks After Treatment for Alcohol or Drug Dependence and Major Depression: Disentangling Person and Time-Level Effects. ( 25347018 )
2014
49
Translating the semi-structured assessment for drug dependence and alcoholism in the Western Pacific: rationale, study design and reliability of alcohol dependence. ( 24936588 )
2014
50
Comparison of health care needs of child family members of adults with alcohol or drug dependence versus adults with asthma or diabetes. ( 24799266 )
2014

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

Pathways related to Drug Dependence according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 ACKR1 CHRM2 CNR1 CRH DRD2 DRD3
2
Show member pathways
12.77 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 CRH
3
Show member pathways
11.7 BDNF DRD2 PDYN
4
Show member pathways
11.67 CHRM2 DRD2 DRD3
6 11.64 OPRD1 OPRM1 POMC
7
Show member pathways
11.55 CHRNA6 DRD2 DRD3
8 11.47 ACKR1 CHRM2 CNR1 DRD3
9 10.88 DRD2 DRD3
10 10.17 CRH POMC

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.83 CHRM2 CRH OPRK1 PDYN PENK
2 axon GO:0030424 9.8 CNR1 DRD2 OPRM1 PENK
3 membrane raft GO:0045121 9.78 CNR1 OPRD1 OPRM1 SLC6A4
4 postsynaptic membrane GO:0045211 9.76 CHRM2 CHRNA6 CHRNB3 OPRD1
5 dendrite GO:0030425 9.73 CHRM2 DRD2 OPRK1 OPRM1 PDYN PENK
6 neuron projection GO:0043005 9.63 CHRNB3 OPRD1 OPRK1 OPRL1 OPRM1 SLC6A4
7 dendrite membrane GO:0032590 9.52 OPRD1 OPRM1
8 acetylcholine-gated channel complex GO:0005892 9.51 CHRNA6 CHRNB3
9 symmetric synapse GO:0032280 9.4 CHRM2 PENK
10 perikaryon GO:0043204 9.35 CRH DRD2 OPRK1 OPRM1 PENK
11 axon terminus GO:0043679 9.1 CHRM2 DRD2 OPRD1 OPRK1 PDYN PENK
12 plasma membrane GO:0005886 10.17 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2
13 integral component of plasma membrane GO:0005887 10.02 CHRM2 CNR1 DRD2 DRD3 OPRD1 OPRK1

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.93 DRD2 DRD3 OPRK1 OPRM1 PENK
2 sensory perception of pain GO:0019233 9.91 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PENK
3 response to toxic substance GO:0009636 9.89 DRD2 PENK SLC6A4
4 response to nicotine GO:0035094 9.89 CHRNA6 CHRNB3 CNR1 DRD2 PENK
5 response to estradiol GO:0032355 9.88 OPRL1 PENK SLC6A4
6 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.87 OPRD1 OPRK1 OPRL1 OPRM1
7 response to ethanol GO:0045471 9.87 CNR1 CRH DRD2 DRD3 OPRK1 OPRM1
8 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.86 CHRM2 CNR1 OPRD1 OPRM1
9 excitatory postsynaptic potential GO:0060079 9.85 CHRNA6 CHRNB3 OPRM1
10 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.85 OPRD1 OPRK1 OPRM1
11 negative regulation of blood pressure GO:0045776 9.85 CNR1 CRH DRD2 DRD3 OPRL1
12 learning or memory GO:0007611 9.84 CNR1 CRH DRD3
13 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.84 CHRM2 CNR1 DRD2
14 response to radiation GO:0009314 9.83 OPRK1 OPRM1 PENK
15 regulation of sensory perception of pain GO:0051930 9.83 OPRD1 OPRK1 OPRL1 OPRM1
16 negative regulation of adenylate cyclase activity GO:0007194 9.82 DRD2 DRD3 OPRM1
17 eating behavior GO:0042755 9.81 OPRD1 OPRK1 OPRL1 OPRM1
18 neuropeptide signaling pathway GO:0007218 9.8 OPRD1 OPRK1 OPRL1 OPRM1 PDYN PENK
19 synaptic transmission, cholinergic GO:0007271 9.79 CHRM2 CHRNA6 CHRNB3
20 opioid receptor signaling pathway GO:0038003 9.78 OPRD1 OPRK1 OPRL1 OPRM1
21 regulation of dopamine secretion GO:0014059 9.77 CHRNA6 DRD2 DRD3
22 behavioral response to cocaine GO:0048148 9.77 DRD2 DRD3 OPRK1
23 synaptic transmission, dopaminergic GO:0001963 9.76 CRH DRD2 DRD3
24 estrous cycle GO:0044849 9.75 OPRK1 OPRL1 OPRM1
25 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
27 negative regulation of cAMP biosynthetic process GO:0030818 9.72 OPRL1 OPRM1
28 behavioral response to ethanol GO:0048149 9.72 DRD2 OPRM1
29 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.71 CRH OPRM1
30 startle response GO:0001964 9.71 DRD2 PENK
31 dopamine metabolic process GO:0042417 9.71 DRD2 DRD3
32 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 OPRL1
33 locomotory exploration behavior GO:0035641 9.7 CRH PENK
34 prepulse inhibition GO:0060134 9.7 DRD2 DRD3
35 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
36 positive regulation of urine volume GO:0035810 9.69 DRD2 OPRL1
37 regulation of synaptic transmission, GABAergic GO:0032228 9.69 CNR1 DRD2
38 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 DRD3
39 behavior GO:0007610 9.68 OPRK1 OPRL1
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
41 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 OPRM1
42 regulation of cAMP metabolic process GO:0030814 9.67 DRD2 DRD3
43 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.66 DRD2 DRD3
44 positive regulation of behavioral fear response GO:2000987 9.65 CRH PENK
45 negative regulation of dopamine secretion GO:0033602 9.64 CNR1 DRD2
46 negative regulation of luteinizing hormone secretion GO:0033685 9.64 CRH OPRK1
47 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3
48 acid secretion GO:0046717 9.63 DRD2 DRD3
49 response to histamine GO:0034776 9.62 DRD2 DRD3
50 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.61 OPRK1 OPRM1

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.91 ACKR1 CHRM2 CNR1 DRD2 DRD3 OPRD1
2 signal transducer activity GO:0004871 9.85 CNR1 DRD2 DRD3 OPRD1 OPRL1 OPRM1
3 drug binding GO:0008144 9.55 CHRM2 CHRNB3 CNR1 DRD2 DRD3
4 acetylcholine binding GO:0042166 9.52 CHRNA6 CHRNB3
5 acetylcholine-gated cation-selective channel activity GO:0022848 9.51 CHRNA6 CHRNB3
6 neuropeptide hormone activity GO:0005184 9.5 CRH PDYN PENK
7 dopamine binding GO:0035240 9.49 DRD2 DRD3
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD2 DRD3
9 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD3
10 opioid receptor binding GO:0031628 9.43 PDYN PENK
11 opioid peptide activity GO:0001515 9.4 PDYN PENK
12 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
13 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Drug Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....